Juno Therapeutics, Inc. (NASDAQ:JUNO) recently saw its volume around 1.35 million shares and on average it trades 2.64 million shares a day. The opening price of $42.76, led it to gain 0.19% to reach $43.08 upon the closing bell.Juno Therapeutics, Inc. (JUNO) Analyst Opinion
Juno Therapeutics, Inc. has a consensus outperform rating from 14 Wall Street analysts, and the number of shares currently sold short amount to at least 15.88% of shares outstanding. The stock sank -4.94% last month and is up 128.54 this year. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover JUNO having a buy-equivalent rating. Analysts have placed a $35.75 price target on Juno Therapeutics, Inc., suggesting a -17.01% decline from recent close. It’s currently trading about -8.4% below its 52-week high.
Juno Therapeutics, Inc. (JUNO) failed to surprise the stock market in its last reported earnings when it earned -$0.74 a piece versus the consensus-estimated -$0.73. Its revenue totaled $15.82 million down -18.16% from the previous quarter.Juno Therapeutics, Inc. (NASDAQ:JUNO) Intraday View
This stock (JUNO) is ahead of its 52-week low with 145.89%. Its last month’s stock price volatility remained 3.4% which for the week stands at 4.49%. The share price has moved backward from its 20 days moving average, trading at a distance of -2.05% and stays 13.56% away from its 50 days moving average. Over the last five days, shares have faced -3.67% losses and now is up 57.73% since hitting its 200-day moving average of $30.05. Juno Therapeutics, Inc. (JUNO) has made its way to a 12-month gain of 59.03%.
Turning to JPMorgan Chase & Co. (NYSE:JPM), its shares were trading at $95.99 a retreat of $-0.85, on the trading floor. The stock, after opening at $97.3, touched a high of $97.5 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.5. JPMorgan Chase & Co. has 7 buy ratings, 13 holds and 2 sells even after the stock tumbled -1.69% from its high of $97.64 to a $343.08 billion market value through last close.
The company’s consensus rating on Reuter’s scale improved from 2.34 to 2.41 during a month. Analysts set a 12-month price target of $96 a share. The target implies a 0.01% spike from where the shares are currently trading. Also, the current price highlights a discount of 15.64% to analysts’ high consensus price target.JPMorgan Chase & Co. (NYSE:JPM) Intraday Trading
The counter witnessed a trading volume of 18.42 million shares versus an average volume of 12.02 million shares during last trading session. Its last month’s stock price volatility remained 1.21% which for the week approaches 1.2%. The lowest price the stock reached in the last trading day was $95.62 and compares with the $66.74 52-week low. The stock recovered 43.84% since its low point and has performed 11.24% year-to-date.